Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute.
- DOI
- 10.1016/j.clbc.2014.09.007
- Published
- 2014-10-02
- Container
- Clin Breast Cancer
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.clbc.2014.09.007,
title = {Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute.},
author = {Yardley DA and Zubkus JD and Eakle JF and Bechhold RG and Finney L and Daniel D and Daniel B and Hainsworth JD.},
year = {2015},
journal = {Clin Breast Cancer},
doi = {10.1016/j.clbc.2014.09.007},
url = {https://doi.org/10.1016/j.clbc.2014.09.007}
}RIS
TY - JOUR TI - Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute. AU - Yardley DA AU - Zubkus JD AU - Eakle JF AU - Bechhold RG AU - Finney L AU - Daniel D AU - Daniel B AU - Hainsworth JD. PY - 2015 JO - Clin Breast Cancer DO - 10.1016/j.clbc.2014.09.007 UR - https://doi.org/10.1016/j.clbc.2014.09.007 ER -
APA
DA, Y., JD, Z., JF, E., RG, B., L, F., D, D., B, D., & JD., H. (2015). Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute.. Clin Breast Cancer. https://doi.org/10.1016/j.clbc.2014.09.007
Source records
- europe-pmc · retrieved 2026-09-27T00:39:40.866Z